Prescribing InformationFor Patients

Personalized care, every step of the way

Get your patient started on XERMELO

Step 1

Download and print the enrollment form

Enrollment Form

Step 2

You and your patient need to sign the enrollment form. Then fax the form to one of the following specialty pharmacies:

Fax: 1-800-823-4506
Phone: 1-800-850-4306
Fax: 1-866-810-7998
Phone: 1-855-611-3408

For questions or to learn more, call: 1-844-XERMELO (937-6356)

Step 3

TerSera SupportSource will verify insurance coverage, identify any available financial assistance, and arrange prescription delivery with your patient

Download the step-by-step guide:

Reducing or eliminating out-of-pocket costs*

TerSera SupportSource specialty pharmacy partners (Diplomat and Biologics) will help determine your patient's insurance coverage.

For patients with commercial insurance:
For patients with Medicare/Medicaid or no insurance:
*TerSera SupportSource offers $0 copay up to $10,000/year. The LexCares specialty pharmacy will process the copay.
TerSera SupportSource will help identify an appropriate patient assistance program if available for qualifying patients.

Our specialty pharmacies can help at every turn

TerSera SupportSource has partnered with Diplomat and Biologics specialty pharmacies to guide patients through getting and starting on XERMELO. Diplomat and Biologics are patient-focused specialty pharmacies and are committed to being a part of the care team.

Diplomat and Biologics will coordinate with patients, physicians, nurses, and office staff to ensure everyone has the most up-to-date information.

TerSera SupportSource will connect with the physician’s office if additional forms or information is required.

Access the forms and info you need to support your patients on XERMELO.

* Eligibility Criteria

Eligibility cannot be determined until all of the information submission requirements have been met by the healthcare professional, patient, and/or caregiver. Please refer to the Enrollment Form for details.

Patient financial information and insurance status are required to determine whether a patient qualifies for assistance, and which TerSera SupportSource financial support offering is appropriate for the patient.

Patients not eligible for financial assistance through TerSera SupportSource may be able to obtain financial support through other programs. Our representatives will assist you in finding other options.

You may report an adverse event related to TerSera Therapeutics products by calling 1-844-334-4035 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.

Xermelo® is a registered trademark of TerSera Therapeutics LLC or its affiliates.
© 2020 TerSera Therapeutics LLC. All rights reserved.
XER-P-0040V2 (10/2020)

Important Safety Information and Indication

Important Safety Information

For more information about XERMELO see Full Prescribing Information

  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: The most common adverse reactions (≥5%) include nausea, headache, increased gammaglutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.


  • XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

For more information about XERMELO see Full Prescribing Information